Latest news
Alphamab’s Anbenitamab Breast Cancer NDA Gains Priority Review in China - TipRanksTipRanks · Tue, 04 Aug 2026 23:16:06 GMTPathos AI Enters Two lIcensing Deals | PharmExec - Pharmaceutical ExecutivePharmaceutical Executive · Tue, 04 Aug 2026 19:07:22 GMTPathos AI Closes $2.3B Cancer Drug Deals to Prove AI Can Design Smarter Trials - Tech TimesTech Times · Tue, 04 Aug 2026 19:03:51 GMTPathos AI inks deals with AstraZeneca and Alphamab - The Pharma LetterThe Pharma Letter · Tue, 04 Aug 2026 14:40:35 GMTM&A Roundup: Pathos AI Enter’s Licensing Agreements with AstraZeneca & Alphamab Oncology, Curium Enters Merger Agreement with Lantheus - Pharmaceutical ExecutivePharmaceutical Executive · Tue, 04 Aug 2026 14:07:34 GMTPathos AI Secures Global Rights to Alphamab's Experimental Breast Cancer Drug in Up to $1.5 Billion Deal - Voice of HealthcareVoice of Healthcare · Tue, 04 Aug 2026 13:55:12 GMTPathos inks back-to-back cancer contracts with AstraZeneca, China’s Alphamab - BioSpaceBioSpace · Tue, 04 Aug 2026 12:15:52 GMTPathos AI strikes deals with Alphamab and AstraZeneca to build AI-native oncology pipeline - Manufacturing ChemistManufacturing Chemist · Tue, 04 Aug 2026 12:09:55 GMT